x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor"s note: Episodes

health & fitness medicine

All Episodes

11:34

Real-World Experience with Dexcom Stelo

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/09/11

In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into their experience with the Dexcom Stelo. The Dexcom Stelo is the first FDA-cleared over-the-counter glucose sensor. Cleared by the FDA on March 05, 2024, the Stelo is indicated for use by anyone 18 years and older who does not use insulin, such as individuals with diabetes treating their condition with oral medications, or those

en-us

20:58

Sotagliflozin for T1D and Other ADCES Highlights

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/08/21

This episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, our second related to the Association of Diabetes Care and Education Specialists (ADCES) 2024 annual meeting, spotlights new data and perspectives from the meeting brought forth by pharmaceutical and diabetes technology companies. Check out our first episode related to ADCES 2024. A large theme of the episode is discussion around data and interactions with Lexicon, which announced the resubmission of a New

en-us

7:57

First 10 Prices Announced from CMS Price Negotiations

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/08/19

On August 15, 2024, the Biden-Harris Administration announced the price list for the first 10 drugs selected as part of the Medicare price negotiations between the United States Department of Health and Human Services (HHS) and pharmaceutical manufacturers.“Americans pay too much for their prescription drugs. That makes today’s announcement historic. For the first time ever, Medicare negotiated directly with drug companies and the American people are better off for it,” said HHS Secretary Xavier

en-us

25:15

Navigating ADCES 2024

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/08/19

The Association of Diabetes Care and Education Specialists (ADCES) is an organization ahead of its time in the world of healthcare. Often, those in medicine find the field to be reactionary instead of proactive in addressing the rising burden of chronic disease. The ADCES, formerly the American Association of Diabetes Educators, was founded in 1973 to support and educate clinicians, care providers, and patients of the latest advancements to improve care and quality of life for people with

en-us

22:41

SUMMIT and FINEARTS-HF, with Muthiah Vaduganathan,...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/08/10

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Muthiah Vaduganathan, MD, MPH, cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials, the latter of which Vaduganathan served on as a trial investigator. Video Version:

en-us

14:20

Simplera CGM and Medtronic's Partnership with Abbott

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/08/10

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, take a break from the Annual Conference of the Association of Diabetes Care and

en-us

23:55

CATALYST Trial and Hypercortisolism in T2D, with John...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/08/02

Even with the second half of the trial yet to be completed, results of the CATALYST trial have initiated a potentially seismic shift in discussions around the management of type 2 diabetes.With the first part of the trial suggesting approximately 1-in-4 patients with difficult-to-control type 2 diabetes, results suggest hypercortisolism could be an underlying driver of suboptimal disease management for millions of people with type 2 diabetes in the US. Now, with this knowledge in hand, the

en-us

21:23

New Early-Stage T1D Monitoring Guidance, with...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

Less than a month after rebranding from JDRF to Breakthrough T1D, the leading type 1 diabetes advocacy organization has now released new consensus guidance related to the monitoring of early-stage type 1 diabetes.Debuted on the final day of the 84th American Diabetes Association Scientific Sessions, the consensus document seeks to fill a gap in guidance around autoantibody-positive individuals in early-stage type 1 diabetes as the community develops new means to delay or prevent progression of the

en-us

24:58

INHALE-3 and Diabetes Tech Updates, with Grazia...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

At the 84th American Diabetes Association (ADA) Scientific Sessions, INHALE-3 was among the trials to take center stage. A phase 4 trial comparing the use of inhaled insulin (Afrezza) against standard care, results demonstrated use of inhaled insulin, in addition to insulin degludec, was associated with improved HbA1c in patients with type 1 diabetes, with an improvement of 0.5% or greater observed among 21% of those on inhaled insulin and 5% of those with usual care. At the meeting, study

en-us

18:16

Blue Circle Health, with Monica Gomberg, MD

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

Despite being a chronic autoimmune disease, the burden of type 1 diabetes is often overlooked in public health discussions. Not only are patients with type 1 diabetes being tasked with understanding disease pathophysiology as an integral part of optimal management, but also with keeping up with advances in pharmacotherapy and technology. As a result, patient support programs, such as Blue Circle Health, have emerged to fill a vital role in the management teams for people with diabetes. Provided at

en-us

23:48

Advances in AID and CGM at ADA 2024, with Davida...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

In this special edition episode from the 84th American Diabetes Association Scientific Sessions, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Davida Kruger, NP, a certified nurse practitioner in the Division of Endocrinology at Henry Ford Health System in Detroit. During the episode, Kruger takes hosts on a deep dive into the latest in diabetes technology at the meeting, with a focus on advancement in automated insulin delivery and continuous glucose monitoring (CGM)

en-us

12:04

ADA Introduces Obesity Association, with Robert...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

On the opening day of the 84th American Diabetes Association Scientific Sessions, the ADA ushered in a new era for their organization with the announcement of the formation of the Obesity Association. Created more than a decade after the American Medical Association recognized obesity as a disease, the new subdivision of the ADA was created to further the organization’s mission of advocating for and advancing treatment for patients. According to a news release, the ADA intends to develop a Standards

en-us

18:11

Patient Considerations for Inhaled Insulin, with...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

In this special edition recorded at the 84th American Diabetes Association Scientific Sessions, Carol Levy, MD, director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research, joins the podcast for a deep dive into the INHALE-3 trial and how to incorporate individual patient-level factors into the management strategy of patients with type 1 diabetes who could benefit from inhaled insulin (Afrezza). Their second on-site episode focused on the INHALE-3 trial, hosts Diana Isaacs,

en-us

32:11

ADA 2024 Diabetes Technology Recap

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/07/18

This special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives focuses on top highlights and updates in diabetes technology from the 84th American Diabetes Association Scientific Sessions. In the episode, hosts Omnipod 5 and the SECURE-T2D trial, a study comparing use of simplified meal announcement vs precise carbohydrate counting with the Medtronic MiniMed 780G, and real-world data from Tandem pump users. Later in the episode, hosts discuss their

en-us

24:16

June 2024 Updates in Diabetes Technology and T1D

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/06/17

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management. In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with

en-us

21:09

GLAM and CRISTAL, Updates in Pregnancy

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/06/05

In this episode, hosts provide their audience with an overview of a pair of new studies on the topic of diabetes in pregnancy: the GLAM and CRISTAL studies.

en-us

13:32

FLOW Trial and Semaglutide's Benefit in Chronic...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/05/31

To celebrate the FLOW trial and break down what it means for people with type 2 diabetes and CKD, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recorded a special edition episode to discuss the clinical application of this trial, unmet need in CKD management, the future of incretin therapies, and more!Chapters: 00:00 - Intro 00:40 - FLOW Background 02:55 - FLOW Results 07:08 - Combination with SGLT2 Inhibitors 12:00 - Future Implications

en-us

23:31

2024 ACP Type 2 Diabetes Recommendations

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/04/20

The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024, the pair of recommendations reflect the findings from a systematic review and network meta-analysis and cost-effectiveness analysis assessing the value of these therapies as both monotherapies and in

en-us

23:31

STEP HFpEF DM and Fair Allocation of Incretin-Based...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/04/20

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.

en-us

31:29

What to Know about Sequel Med Tech's twiist AID...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2024/03/30

The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and flow of inulin delivered with every micro-dose.In this episode, Alan Lotvin, MD, co-founder and CEO of

en-us

172 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown